5-(pyrrolidin-1-yl)quinazoline-2,4-diamine | 215925-79-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-(pyrrolidin-1-yl)quinazoline-2,4-diamine
• 英文别名: 2,4-Diamino-5-(pyrrolidin-1-yl)quinazoline；5-Pyrrolidin-1-ylquinazoline-2,4-diamine
• CAS: 215925-79-4
• 化学式: C₁₂H₁₅N₅
• 分子量: 229.285
• InChiKey: VQJRZFLQDSIQOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  81.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2,6-二氟苯腈 在 potassium carbonate 作用下， 以 N,N-二甲基乙酰胺 、 二甲基亚砜 为溶剂， 反应 8.25h， 生成 5-(pyrrolidin-1-yl)quinazoline-2,4-diamine
  参考文献：
  名称：

  Discovery and Optimization of 2,4-Diaminoquinazoline Derivatives as a New Class of Potent Dengue Virus Inhibitors

  摘要：

  The results of a high-throughput screening assay using the DENV-2 replicon showed that the 2,4-diaminoquinazoline derivative 4a has a high dengue virus inhibitory activity (EC50 = 0.15 mu M). A series of 2,4-diaminoquinazoline derivatives based on 4a as a lead compound were synthesized and subjected to structure-antidengue activity relationship studies. Among the series of 2,4-diaminoquinazoline derivative probed, 4o was observed to display both the highest antiviral potency (EC50 = 2.8 nM, SI > 1000) and an excellent pharmacokinetic profile.

  DOI：

  10.1021/jm2015952

文献信息

• [EN] BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR<br/>[FR] COMPOSÉS BICYCLIQUES AYANT UNE ACTIVITÉ SUR LE RÉCEPTEUR CXCR4
  申请人：ALLERGAN INC

  公开号：WO2009143058A1

  公开（公告）日：2009-11-26

  A compound represented by the structural formula (I): Therapeutic methods, compositions, and medicaments related thereto are also disclosed.

  由结构式(I)表示的化合物：还公开了相关的治疗方法、组合物和药物。
• Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
  申请人：——

  公开号：US20010014679A1

  公开（公告）日：2001-08-16

  The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to quinazoline compounds and pharmaceutical compositions comprising these compounds.

  本发明部分涉及使用基于喹唑啉的化合物调节丝氨酸/苏氨酸蛋白激酶功能的方法。该方法包括表达丝氨酸/苏氨酸蛋白激酶（例如RAF）的细胞。此外，本发明还描述了使用本发明所确定的化合物预防和治疗有关丝氨酸/苏氨酸蛋白激酶的异常情况的方法。此外，本发明还涉及喹唑啉化合物和包含这些化合物的制药组合物。
• METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS
  申请人：Sugen, Inc.

  公开号：EP0981519A1

  公开（公告）日：2000-03-01
• BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR
  申请人：Allergan, Inc.

  公开号：EP2300456A1

  公开（公告）日：2011-03-30
• US6204267B1
  申请人：——

  公开号：US6204267B1

  公开（公告）日：2001-03-20